ABOTALEB, Mariam, Peter KUBATKA, Martin CAPRNDA, Elizabeth VARGHESE, Barbora ZOLAKOVA, Pavol ZUBOR, Radka OPATRILOVA, Peter KRUŽLIAK, Patrik STEFANICKA a Dietrich BUSSELBERG. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. BIOMEDICINE & PHARMACOTHERAPY. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2018, roč. 101, MAY 2018, s. 458-477. ISSN 0753-3322. Dostupné z: https://dx.doi.org/10.1016/j.biopha.2018.02.108. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1419758, author = {Abotaleb, Mariam and Kubatka, Peter and Caprnda, Martin and Varghese, Elizabeth and Zolakova, Barbora and Zubor, Pavol and Opatrilova, Radka and Kružliak, Peter and Stefanicka, Patrik and Busselberg, Dietrich}, article_location = {Paris}, article_number = {MAY 2018}, doi = {http://dx.doi.org/10.1016/j.biopha.2018.02.108}, keywords = {Metastatic breast cancer; Chemotherapy; Efficacy; Toxicity; Resistance; Antimetabolites; Immunologic therapy; Hormonal/endocrine therapy; DNA alkylating agents; Ion modulators; Antimitotic agents}, language = {eng}, issn = {0753-3322}, journal = {BIOMEDICINE & PHARMACOTHERAPY}, title = {Chemotherapeutic agents for the treatment of metastatic breast cancer: An update}, volume = {101}, year = {2018} }
TY - JOUR ID - 1419758 AU - Abotaleb, Mariam - Kubatka, Peter - Caprnda, Martin - Varghese, Elizabeth - Zolakova, Barbora - Zubor, Pavol - Opatrilova, Radka - Kružliak, Peter - Stefanicka, Patrik - Busselberg, Dietrich PY - 2018 TI - Chemotherapeutic agents for the treatment of metastatic breast cancer: An update JF - BIOMEDICINE & PHARMACOTHERAPY VL - 101 IS - MAY 2018 SP - 458-477 EP - 458-477 PB - ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER SN - 07533322 KW - Metastatic breast cancer KW - Chemotherapy KW - Efficacy KW - Toxicity KW - Resistance KW - Antimetabolites KW - Immunologic therapy KW - Hormonal/endocrine therapy KW - DNA alkylating agents KW - Ion modulators KW - Antimitotic agents N2 - Breast cancer is the second greatest cause of death among women worldwide; it comprises a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and differentiation and the loss of normal programmed cell death. There are different molecular sub-types of breast cancer; therefore, various options are selected for treatment of different forms of metastatic breast cancer. However, the use of chemotherapeutic drugs is usually accompanied by deleterious side effects and the development of drug resistance when applied for a longer period. This review offers a classification of these chemotherapeutic agents according to their modes of action and therefore improves the understanding of molecular targets that are affected during treatment. Overall, it will allow the clinician to identify more specific targets to increase the effectiveness of a drug and to reduce general toxicity, resistance and other side effects. ER -
ABOTALEB, Mariam, Peter KUBATKA, Martin CAPRNDA, Elizabeth VARGHESE, Barbora ZOLAKOVA, Pavol ZUBOR, Radka OPATRILOVA, Peter KRUŽLIAK, Patrik STEFANICKA a Dietrich BUSSELBERG. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. \textit{BIOMEDICINE \&{}amp; PHARMACOTHERAPY}. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2018, roč.~101, MAY 2018, s.~458-477. ISSN~0753-3322. Dostupné z: https://dx.doi.org/10.1016/j.biopha.2018.02.108.
|